Summary: Blackstone Medical Services and EnsoData partner to equip primary care physicians with EnsoSleep PPG.
Key Takeaways:
- The partnership will improve access to sleep testing for people with undiagnosed sleep apnea, the companies state.
- ‘The role of accessible technology has never been more critical,’ says EnsoData’s CEO.
- Ongoing innovation has the potential to continue to improve lives for the millions of people who are undiagnosed.
Blackstone Medical Services, a Medicare-approved, Joint Commission-accredited, and nationally recognized independent diagnostic testing facility for home sleep testing, has partnered with EnsoData to offer improved accessibility to diagnosis and treatment for the millions of patients living with undiagnosed sleep apnea.
Blackstone Medical leverages EnsoData’s US Food and Drug Administration-cleared EnsoSleep PPG home sleep testing solution to equip primary care physicians with a method to reach patients with sleep disorders.
“Our partnership with EnsoData allows us to provide an affordable, accessible at-home solution that is paving the way for fast, accurate diagnoses and better health outcomes nationwide,” says Vick Tipnes, Blackstone Medical CEO, in a release.
“As sleep medicine evolves, the role of accessible technology has never been more critical,” says Justin Mortara, PhD, EnsoData CEO, “EnsoSleep PPG provides [Blackstone Medical] with an avenue to reach more patients, no matter their location or ability to visit traditional sleep labs.
“We are excited about the future of sleep medicine. Continued innovation in sleep diagnostics holds the potential to change the lives of millions who are suffering due to undiagnosed sleep apnea.”
